Jaen Juan C. Form 4 March 01, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Expires: Estimated average burden hours per response...

OMB

Number:

OMB APPROVAL

3235-0287

January 31,

2005

0.5

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person * Jaen Juan C.

2. Issuer Name and Ticker or Trading Symbol

Issuer

(Last)

(Middle)

ChemoCentryx, Inc. [CCXI] 3. Date of Earliest Transaction

(Check all applicable)

C/O CHEMOCENTRYX, INC., 850

(Street)

(First)

(Month/Day/Year)

Director 10% Owner Other (specify _X__ Officer (give title below)

5. Relationship of Reporting Person(s) to

02/27/2013

SVP, Drug Discovery & CSO

MAUDE AVENUE

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year)

Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

MOUNTAIN VIEW, CA 94043

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	e Secu	rities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	(A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2013		Code V M	Amount 2,599	(D)	Price \$ 4.3	47,599	D	
Common Stock	02/27/2013		S <u>(1)</u>	2,599	D	\$ 12.5625 (2)	45,000	D	
Common Stock	02/27/2013		M	4,901	A	\$ 4.3	49,901	D	
Common Stock	02/27/2013		S <u>(1)</u>	4,901	D	\$ 12.5544 (3)	45,000	D	
	02/28/2013		M	99	A	\$ 4.3	45,099	D	

Common Stock							
Common Stock	02/28/2013	S(1)	99	D	\$ 12.56	45,000	D
Common Stock	02/28/2013	M	5,000	A	\$ 4.3	50,000	D
Common Stock	02/28/2013	S(1)	5,000	D	\$ 13.1353 (4)	45,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number proof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 4.3	02/27/2013		M	2,599	<u>(5)</u>	02/06/2017	Common Stock	2,599
Employee Stock Option (right to buy)	\$ 4.3	02/27/2013		M	4,901	<u>(5)</u>	02/06/2017	Common Stock	4,901
Employee Stock Option (right to buy)	\$ 4.3	02/28/2013		M	99	<u>(5)</u>	02/06/2017	Common Stock	99
,	\$ 4.3	02/28/2013		M	5,000	(5)	02/06/2017		5,000

Employee
Stock
Option
(right to buy)

Common Stock

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Jaen Juan C. C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW, CA 94043

SVP, Drug Discovery & CSO

Signatures

/s/ Susan M. Kanaya, as Attorney-in-Fact

03/01/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$12.36 to (2) \$12.85 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$12.36 to (3) \$12.85 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$12.56 to \$13.40 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- (5) As of February 27, 2013 and prior to this transaction, the option fully vested.
- (6) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3